Skip to main content
Top
Gepubliceerd in: Bijblijven 6/2018

04-06-2018

Medicamenteuze behandeling van hartfalen

Auteur: Dr. Evert J. P. Lamfers

Gepubliceerd in: Bijblijven | Uitgave 6/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

In 2008 introduceerde de kleurrijke Engelse hartfalenpioneer Philip Poole-Wilson de begrippen hartfalen met verminderde en hartfalen met bewaarde ejectiefractie; sindsdien is de medicamenteuze behandeling van hartfalen hierop gebaseerd. In deze bijdrage wordt een overzicht hiervan gegeven, enigszins op historische basis, waarbij gebruik wordt gemaakt van de laatste richtlijnen van de European Society of Cardiology (2016) met aangeven van adviesklasse en bewijskracht. Deze richtlijnen worden eveneens gebruikt in het CONNECT-hartfalenprogramma, dat onder auspiciën van de Nederlandse Vereniging voor Cardiologie is opgesteld en waarin huisartsengroepen van diverse regio’s in Nederland actief worden betrokken bij het vervolgbeleid van deze patiënten.
Literatuur
1.
go back to reference The consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med. 1987;316:1429–39.CrossRef The consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med. 1987;316:1429–39.CrossRef
2.
go back to reference Voors AA. Medicamenteuze behandeling van chronisch hartfalen. In: Meursing BTJ, Lamfers EJP, redactie. Handboek Hartfalen. Houten: Bohn Stafleu van Loghum; 2011. Voors AA. Medicamenteuze behandeling van chronisch hartfalen. In: Meursing BTJ, Lamfers EJP, redactie. Handboek Hartfalen. Houten: Bohn Stafleu van Loghum; 2011.
3.
go back to reference Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;2016(37):2129–200. Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;2016(37):2129–200.
4.
go back to reference Waagstein F, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopthy. Br Med J. 1975;37:1022–36. Waagstein F, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopthy. Br Med J. 1975;37:1022–36.
5.
go back to reference Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–17.CrossRef Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–17.CrossRef
6.
go back to reference For the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.CrossRef For the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.CrossRef
7.
go back to reference On behalf of the SHIFT Investigators, Swedberg K, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;9744:875–85. On behalf of the SHIFT Investigators, Swedberg K, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;9744:875–85.
8.
go back to reference For the PARADIGM-HF trial, Packer M, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1000.CrossRef For the PARADIGM-HF trial, Packer M, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1000.CrossRef
9.
go back to reference ARISTOTLE investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71:1063–74.CrossRef ARISTOTLE investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71:1063–74.CrossRef
10.
go back to reference EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.CrossRef EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.CrossRef
11.
go back to reference Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–48.CrossRefPubMed Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–48.CrossRefPubMed
12.
go back to reference Ponikowski P, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657–68.CrossRefPubMed Ponikowski P, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657–68.CrossRefPubMed
13.
go back to reference Lamfers EJP. Hartfalen en dehydratie. In: Meursing BTJ, Lamfers EJP, redactie. Handboek Hartfalen. Houten: Bohn Stafleu van Loghum; 2011. Lamfers EJP. Hartfalen en dehydratie. In: Meursing BTJ, Lamfers EJP, redactie. Handboek Hartfalen. Houten: Bohn Stafleu van Loghum; 2011.
14.
go back to reference Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2015;3:647–53.CrossRefPubMedPubMedCentral Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2015;3:647–53.CrossRefPubMedPubMedCentral
15.
go back to reference Teerlink JR, et al. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388:2895–903.CrossRefPubMed Teerlink JR, et al. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388:2895–903.CrossRefPubMed
Metagegevens
Titel
Medicamenteuze behandeling van hartfalen
Auteur
Dr. Evert J. P. Lamfers
Publicatiedatum
04-06-2018
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Bijblijven / Uitgave 6/2018
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI
https://doi.org/10.1007/s12414-018-0323-5

Andere artikelen Uitgave 6/2018

Bijblijven 6/2018 Naar de uitgave

OriginalPaper

Hartfalen en COPD